For research use only. Not for therapeutic Use.
D-Leucine-d10 is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro[1].
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
Catalog Number | I043741 |
CAS Number | 271247-12-2 |
Synonyms | (2R)-2-amino-2,3,3,4,5,5,5-heptadeuterio-4-(trideuteriomethyl)pentanoic acid |
Molecular Formula | C6H3D10NO2 |
Purity | ≥95% |
InChI | InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m1/s1/i1D3,2D3,3D2,4D,5D |
InChIKey | ROHFNLRQFUQHCH-MSQIRGOSSA-N |
SMILES | CC(C)CC(C(=O)O)N |
Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Xiaoyu Cao, et al. Combination of PARP Inhibitor and Temozolomide to Suppress Chordoma Progression. J Mol Med (Berl). 2019 Aug;97(8):1183-1193 |